NDA 216993 · Daiichi Sankyo INC
Vanflyta
Quizartinib Dihydrochloride · Oral
NovelPriority reviewOrphanCDER novel approval, Jul 20, 2023: To use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteria
Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Jul 20, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
0 Phase 3, 1 recruiting
FAERS reports
702
451 serious, 107 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: QT PROLONGATION, TORSADES DE POINTES, and CARDIAC ARREST VANFLYTA prolongs the QT interval in a dose- and concentration-related manner [see Clinical Pharmacology (12.2) ] . Prior to VANFLYTA administration and periodically, monitor for hypokalemia or hypomagnesemia, and correct deficiencies. Perform ECGs to monitor the QTc at baseline, weekly during induction and consolidation therapy, weekly for at least the first month of maintenance, and periodically thereafter [see Dosage and Administration (2.3) and Warnings and Precautions (5.1) ]. Torsades de pointes and cardiac arrest have occurred in patients receiving VANFLYTA. Do not administer VANFLYTA to patients with severe hypokalemia, severe hypomagnesemia, or long QT syndrome [see Contraindications (4) and Warnings and Precautions (5.1) ] . Do not initiate treatment with VANFLYTA or escalate the VANFLYTA dose if the QT interval...
What it is approved for
From the label in effect Apr 16, 2026.
VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test [see Dosage and Administration (2.1) and Clinical Studies (14) ] . VANFLYTA is a kinase inhibitor indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. ( 1 ) Limitations of Use: VANFLYTA is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with VANFLYTA in this setting has not been demonstrated. ( 1 ) Limitations of Use VANFLYTA is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with VANFLYTA in this setting has not been demonstrated [see Clinical Studies (14) ] .
Mechanism: Quizartinib is a small molecule inhibitor of the receptor tyrosine kinase FLT3. Quizartinib and its major active metabolite AC886 bind to the adenosine triphosphate (ATP) binding domain of FLT3 with comparable affinity, and both had 10-fold lower affinity towards FLT3-ITD mutation compared to FLT3 in a binding assay. Quizartinib and AC886 inhibited FLT3 kinase activity, preventing autophosphorylation of the receptor, thereby inhibiting downstream FLT3 receptor signaling and blocking FLT3-ITD-dependent cell proliferation. Quizartinib showed antitumor activity in a mouse model of...
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 20, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelMedication GuideLetter
2 products under this application
- VANFLYTA · QUIZARTINIB DIHYDROCHLORIDE EQ 26.5MG BASE · TABLET, ORAL · Prescription
- VANFLYTA · QUIZARTINIB DIHYDROCHLORIDE EQ 17.7MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Quizartinib Dihydrochloride" as an intervention, any sponsor and status, largest first.
Ruijin HospitalAcademic, hospital or other
NCT07548710 · 205 participants (planned) · Start May 1, 2026 · Primary completion May 31, 2027
Drug: Anthracycline; Ivosidenib and 4 more · For: Acute Myeloid Leukemia
Sites: Shanghai, China
- Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the BloodActive, not recruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT03793478 · 65 participants (planned) · Start Aug 15, 2018 · Primary completion May 1, 2027
Drug: Quizartinib; Fludarabine and 3 more · For: Acute Myeloid Leukemia
Sites: Loma Linda, California; San Francisco, California; Aurora, Colorado · 27 sites in all
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT04796831 · 8 participants · Start Apr 26, 2021 · Primary completion Jun 11, 2021
Drug: Quizartinib dihydrochloride; 14C-Quizartinib solution for infusion · For: Healthy Subjects
Sites: Nottingham, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use79
- no adverse event71
- death56
- nausea50
- platelet count decreased49
- pyrexia43
- febrile neutropenia39
- fatigue37
- disease progression35
- electrocardiogram qt prolonged35
- infection35
- product dose omission issue32
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 14 |
| 2020 | 7 |
| 2021 | 13 |
| 2022 | 6 |
| 2023 | 34 |
| 2024 | 165 |
| 2025 | 239 |
| 2026 | 217 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vanflyta (Quizartinib Dihydrochloride)
2024 spending
$7.9M
Beneficiaries
106
434 claims
Per beneficiary
$74,108
$533.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $1,145,286 |
| 2024 | $7,855,421 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.
Altman JK, Foran JM, Pratz KW, et al. · Am J Hematol 2018 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.
Cortes JE, Tallman MS, Schiller GJ, et al. · Blood 2018 · Clinical Trial, Phase II, Comparative Study
- Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.
Sandmaier BM, Khaled S, Oran B, et al. · Am J Hematol 2018 · Clinical Trial, Phase I, Multicenter Study
- Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
Papadopoulos KP, Ben-Ami E, Patnaik A, et al. · BMC Cancer 2018 · Clinical Trial, Phase I, Multicenter Study
Sponsor: Daiichi Sankyo
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.